Pang Paul Ha-Sang, Chan Kin-Tak, Tse Luigi Ying-Wai, Chan Ray Chun-Fai, Cheung Ying-Kit, Sin Fion Wan-Yee, Guo Zhi-Hong, Xie Yong
Department of Biology, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China.
Cancer Lett. 2007 Oct 28;256(2):178-85. doi: 10.1016/j.canlet.2007.06.002. Epub 2007 Jul 10.
HCA661 is a cancer-testis (CT) antigen frequently expressed in human hepatocellular carcinoma (HCC). To search for immunogenic peptides of HCA661, bioinformatics analysis and CD8(+) T cell IFN-gamma ELISPOT assay were employed, and two HLA-A *0201 restricted peptides, H110 and H246, were identified. These two HCA661 peptides are naturally processed in dendritic cells (DCs) and when used for DCs loading, they are sufficient to prime autologous CD8(+) T cells to elicit cytotoxic response against HCA661(+) human cancer cells. The HCA661 peptides, H110 and H246, are hence attractive candidates for human cancer immunotherapy.
HCA661是一种癌-睾丸（CT）抗原，在人类肝细胞癌（HCC）中经常表达。为了寻找HCA661的免疫原性肽段，采用了生物信息学分析和CD8(+) T细胞干扰素-γ ELISPOT检测，鉴定出两种HLA-A *0201限制性肽段H110和H246。这两种HCA661肽段在树突状细胞（DCs）中自然加工，当用于DCs负载时，它们足以激活自体CD8(+) T细胞，以引发针对HCA661(+)人类癌细胞的细胞毒性反应。因此，HCA661肽段H110和H246是人类癌症免疫治疗的有吸引力的候选物。
